Pieris

Contact
pieris.com
+4981611411400

Pieris AG

Lise-Meitner-Straße 30
85354 Freising
Germany
+4981611411400
pieris.com
Contact
Profile Products News
Contact

About Pieris

Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins®, a novel class of targeted human proteins designed to diagnose and treat serious human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of Anticalin product candidates.

Read more about Pieris
Facts about Pieris
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of Pieris

Product portfolio

Show all

News about Pieris

Pieris

19-May-2015 | people

Pieris Pharmaceuticals Appoints Jean-Pierre Bizzari, M.D., to its Board of Directors

Pieris Pharmaceuticals, Inc. announced that Jean-Pierre Bizzari, M.D. has joined the Company's Board bringing the total number of directors to six. Dr. ...

Read news
Pieris

01-Apr-2015 | business & finance

Pieris Pharmaceuticals and The University of Melbourne Receive Research Grant to Advance Immunological Diseases Program

Pieris Pharmaceuticals, Inc. (OTCQB:PIRS) and The University of Melbourne announced the receipt by the University of a research grant to further develop ...

Read news
Pieris

15-Dec-2014 | research and development

Pieris Initiates Phase I Clinical Trial for Anticalin® to Treat Anemia

Pieris AG announced the initiation of a Phase I clinical trial with PRS-080, an anti-hepcidin Anticalin® therapeutic protein designed to treat anemia. The ...

Read news
Pieris

26-Jun-2014 | research and development

Pieris Achieves Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin Therapeutics

Pieris AG announced that it has achieved a second milestone for its second program, and fifth milestone overall, in its discovery and development ...

Read news
Pieris

12-Feb-2014 | business & finance

Pieris achieves milestone payment in Sanofi collaboration

Pieris AG has achieved a preclinical milestone within its R&D collaboration with Sanofi, triggering an undisclosed payment, the company announced. The ...

Read news
Pieris

20-Nov-2013 | research and development

Pieris Receives Third Milestone Payment in Daiichi Sankyo Collaboration

Pieris AG has achieved its third milestone overall in its discovery and development collaboration with Daiichi Sankyo Company Limited, triggering an ...

Read news
Pieris

09-Feb-2012 | business & finance

Pieris Receives BMBF Grant to Fund PRS-110 c-Met Antagonist Anticalin Program

Grant Supports Personalized Anti-cancer Approach on Path to Clinic

Read news
Pieris

25-Oct-2011 | business & finance

EUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat Anemia

Consortium Will Receive Six Million Euro from Seventh Framework Programme

Read news
Show more news about Pieris

Here you will find Pieris AG